Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Research

Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer

Authors: Xiaotao Li, Shi Fu, Yinglong Huang, Ting Luan, Haifeng Wang, Jiansong Wang

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Bladder cancer (BC) is one of the most common malignancies and has a relatively poor outcome worldwide. In this study, we attempted to construct a novel metabolism-related gene (MRG) signature for predicting the survival probability of BC patients.

Methods

First, differentially expressed MRGs between BC and normal samples were identified and used to construct a protein-protein interaction (PPI) network and perform mutation analysis. Next, univariate Cox regression analysis was utilized to select prognostic genes, and multivariate Cox regression analysis was applied to establish an MRG signature for predicting the survival probability of BC patients. Moreover, Kaplan-Meier (KM) survival analysis and receiver operating characteristic (ROC) analysis were performed to evaluate the predictive capability of the MRG signature. Finally, a nomogram based on the MRG signature was established to better predict the survival of BC.

Results

In the present study, 27 differentially expressed MRGs were identified, most of which presented mutations in BC patients, and LRP1 showed the highest mutation rate. Next, an MRG signature, including MAOB, FASN and LRP1, was established by using univariate and multivariate Cox regression analysis. Furthermore, survival analysis indicated that BC patients in the high-risk group had a dramatically lower survival probability than those in the low-risk group. Finally, Cox regression analysis showed that the risk score was an independent prognostic factor, and a nomogram integrating age, pathological tumor stage and risk score was established and presented good predictive ability.

Conclusion

We successfully constructed a novel MRG signature to predict the prognosis of BC patients, which might contribute to the clinical treatment of BC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
2.
3.
go back to reference Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of nonmetastatic muscle-invasive bladder Cancer: American urological association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017;13(9):621–5.PubMedCrossRef Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of nonmetastatic muscle-invasive bladder Cancer: American urological association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017;13(9):621–5.PubMedCrossRef
4.
go back to reference von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.PubMedCrossRef von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.PubMedCrossRef
5.
go back to reference Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42(1):50–4.PubMedCrossRef Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42(1):50–4.PubMedCrossRef
6.
go back to reference Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced Urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.PubMedPubMedCentralCrossRef Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced Urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.PubMedPubMedCentralCrossRef
8.
go back to reference Widjaja-Adhi MAK, Golczak M. The molecular aspects of absorption and metabolism of carotenoids and retinoids in vertebrates. Biochim Biophys Acta Mol Cell Biol Lipids. 1865;2020(11):158571. Widjaja-Adhi MAK, Golczak M. The molecular aspects of absorption and metabolism of carotenoids and retinoids in vertebrates. Biochim Biophys Acta Mol Cell Biol Lipids. 1865;2020(11):158571.
9.
go back to reference Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry. 2001;40(18):5542–7.PubMedCrossRef Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry. 2001;40(18):5542–7.PubMedCrossRef
10.
go back to reference Wang G, Wang JJ, Guan R, Du L, Gao J, Fu XL. Strategies to target glucose metabolism in tumor microenvironment on Cancer by flavonoids. Nat Can. 2017;69(4):534–54. Wang G, Wang JJ, Guan R, Du L, Gao J, Fu XL. Strategies to target glucose metabolism in tumor microenvironment on Cancer by flavonoids. Nat Can. 2017;69(4):534–54.
11.
go back to reference Shankaraiah RC, Veronese A, Sabbioni S, Negrini M. Non-coding RNAs in the reprogramming of glucose metabolism in cancer. Cancer Lett. 2018;419:167–74.PubMedCrossRef Shankaraiah RC, Veronese A, Sabbioni S, Negrini M. Non-coding RNAs in the reprogramming of glucose metabolism in cancer. Cancer Lett. 2018;419:167–74.PubMedCrossRef
13.
go back to reference Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011;71(24):7376–86.PubMedPubMedCentralCrossRef Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011;71(24):7376–86.PubMedPubMedCentralCrossRef
14.
go back to reference von Rundstedt FC, Rajapakshe K, Ma J, Arnold JM, Gohlke J, Putluri V, et al. Integrative pathway analysis of metabolic signature in bladder Cancer: a linkage to the Cancer genome atlas project and prediction of survival. Urol J. 2016;195(6):1911–9.CrossRef von Rundstedt FC, Rajapakshe K, Ma J, Arnold JM, Gohlke J, Putluri V, et al. Integrative pathway analysis of metabolic signature in bladder Cancer: a linkage to the Cancer genome atlas project and prediction of survival. Urol J. 2016;195(6):1911–9.CrossRef
15.
go back to reference Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, et al. Distinct Lipidomic landscapes associated with clinical stages of Urothelial Cancer of the bladder. Eur Urol Focus. 2018;4(6):907–15.PubMedCrossRef Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, et al. Distinct Lipidomic landscapes associated with clinical stages of Urothelial Cancer of the bladder. Eur Urol Focus. 2018;4(6):907–15.PubMedCrossRef
16.
go back to reference Li Z, Li X, Wu S, Xue M, Chen W. Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway. Cancer Sci. 2014;105(8):951–5.PubMedPubMedCentralCrossRef Li Z, Li X, Wu S, Xue M, Chen W. Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway. Cancer Sci. 2014;105(8):951–5.PubMedPubMedCentralCrossRef
17.
go back to reference Yang X, Cheng Y, Li P, Tao J, Deng X, Zhang X, et al. A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 2015;36(1):383–91.PubMedCrossRef Yang X, Cheng Y, Li P, Tao J, Deng X, Zhang X, et al. A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 2015;36(1):383–91.PubMedCrossRef
18.
go back to reference Xian S, Shang D, Kong G, Tian Y. FOXJ1 promotes bladder cancer cell growth and regulates Warburg effect. Biochem Biophys Res. 2018;495(1):988–94.CrossRef Xian S, Shang D, Kong G, Tian Y. FOXJ1 promotes bladder cancer cell growth and regulates Warburg effect. Biochem Biophys Res. 2018;495(1):988–94.CrossRef
19.
go back to reference Yeon A, You S, Kim M, Gupta A, Park MH, Weisenberger DJ, et al. Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism. Theranostics. 2018;8(16):4520–34.PubMedPubMedCentralCrossRef Yeon A, You S, Kim M, Gupta A, Park MH, Weisenberger DJ, et al. Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism. Theranostics. 2018;8(16):4520–34.PubMedPubMedCentralCrossRef
20.
go back to reference Wen F, Huang J, Lu X, Huang W, Wang Y, Bai Y, et al. Identification and prognostic value of metabolism-related genes in gastric cancer. Aging. 2020;12(17):17647–61.PubMedPubMedCentralCrossRef Wen F, Huang J, Lu X, Huang W, Wang Y, Bai Y, et al. Identification and prognostic value of metabolism-related genes in gastric cancer. Aging. 2020;12(17):17647–61.PubMedPubMedCentralCrossRef
21.
go back to reference Chen Q, Li F, Gao Y, Xu G, Liang L, Xu J. Identification of energy metabolism genes for the prediction of survival in hepatocellular carcinoma. Front Oncol. 2020;10:1210.PubMedPubMedCentralCrossRef Chen Q, Li F, Gao Y, Xu G, Liang L, Xu J. Identification of energy metabolism genes for the prediction of survival in hepatocellular carcinoma. Front Oncol. 2020;10:1210.PubMedPubMedCentralCrossRef
22.
go back to reference Wu F, Zhao Z, Chai RC, Liu YQ, Li GZ, Jiang HY, et al. Prognostic power of a lipid metabolism gene panel for diffuse gliomas. J Cell Mol Med. 2019;23(11):7741–8.PubMedPubMedCentralCrossRef Wu F, Zhao Z, Chai RC, Liu YQ, Li GZ, Jiang HY, et al. Prognostic power of a lipid metabolism gene panel for diffuse gliomas. J Cell Mol Med. 2019;23(11):7741–8.PubMedPubMedCentralCrossRef
24.
go back to reference Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2016. Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2016.
25.
27.
go back to reference Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef
28.
go back to reference Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.PubMedPubMedCentralCrossRef Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56.PubMedPubMedCentralCrossRef
29.
go back to reference Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61(1):92–105.PubMedCrossRef Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61(1):92–105.PubMedCrossRef
30.
go back to reference Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.PubMedCrossRef Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.PubMedCrossRef
31.
go back to reference Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.PubMedCrossRef Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.PubMedCrossRef
32.
33.
go back to reference Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. Urol J. 2000;163(1):73–8.CrossRef Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. Urol J. 2000;163(1):73–8.CrossRef
34.
go back to reference Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification Systems in non-muscle-invasive Bladder Cancer: a European Association of Urology non-muscle invasive bladder Cancer guidelines panel systematic review. Eur Urol. 2017;72(5):801–13.PubMedCrossRef Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification Systems in non-muscle-invasive Bladder Cancer: a European Association of Urology non-muscle invasive bladder Cancer guidelines panel systematic review. Eur Urol. 2017;72(5):801–13.PubMedCrossRef
35.
go back to reference van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–42.PubMedCrossRef van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–42.PubMedCrossRef
36.
go back to reference Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2019;16(1):23–4.PubMedCrossRef Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2019;16(1):23–4.PubMedCrossRef
37.
go back to reference Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.PubMedCrossRef Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76.PubMedCrossRef
39.
40.
41.
go back to reference Rosario SR, Long MD, Affronti HC, Rowsam AM, Eng KH, Smiraglia DJ. Pan-cancer analysis of transcriptional metabolic dysregulation using the Cancer genome atlas. Nat Commun. 2018;9(1):5330.PubMedPubMedCentralCrossRef Rosario SR, Long MD, Affronti HC, Rowsam AM, Eng KH, Smiraglia DJ. Pan-cancer analysis of transcriptional metabolic dysregulation using the Cancer genome atlas. Nat Commun. 2018;9(1):5330.PubMedPubMedCentralCrossRef
42.
go back to reference Cheng Y, Yang X, Deng X, Zhang X, Li P, Tao J, et al. Metabolomics in bladder cancer: a systematic review. Int J Clin Exp Med. 2015;8(7):11052–63.PubMedPubMedCentral Cheng Y, Yang X, Deng X, Zhang X, Li P, Tao J, et al. Metabolomics in bladder cancer: a systematic review. Int J Clin Exp Med. 2015;8(7):11052–63.PubMedPubMedCentral
43.
go back to reference Edmondson DE. Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. Curr Pharm Des. 2014;20(2):155–60.PubMedCrossRef Edmondson DE. Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. Curr Pharm Des. 2014;20(2):155–60.PubMedCrossRef
44.
go back to reference Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, et al. Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology. 2014;16(9):1186–95.PubMedPubMedCentralCrossRef Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, et al. Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology. 2014;16(9):1186–95.PubMedPubMedCentralCrossRef
45.
go back to reference Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 2010;12(1):49–57.PubMedCrossRef Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 2010;12(1):49–57.PubMedCrossRef
46.
go back to reference Yang YC, Chien MH, Lai TC, Su CY, Jan YH, Hsiao M, et al. Monoamine oxidase B expression correlates with a poor prognosis in colorectal Cancer patients and is significantly associated with epithelial-to-Mesenchymal transition-related gene signatures. Int J Mol Sci. 2020;21(8):2813.PubMedCentralCrossRef Yang YC, Chien MH, Lai TC, Su CY, Jan YH, Hsiao M, et al. Monoamine oxidase B expression correlates with a poor prognosis in colorectal Cancer patients and is significantly associated with epithelial-to-Mesenchymal transition-related gene signatures. Int J Mol Sci. 2020;21(8):2813.PubMedCentralCrossRef
47.
go back to reference Weng L, Shen S, Wu S, Yin X, Liu B, Shang M, et al. Identification of critical genes and proteins for stent restenosis induced by esophageal benign hyperplasia in esophageal Cancer. Front Genet. 2020;11:563954.PubMedPubMedCentralCrossRef Weng L, Shen S, Wu S, Yin X, Liu B, Shang M, et al. Identification of critical genes and proteins for stent restenosis induced by esophageal benign hyperplasia in esophageal Cancer. Front Genet. 2020;11:563954.PubMedPubMedCentralCrossRef
48.
go back to reference Xu N, Wu YP, Ke ZB, Liang YC, Cai H, Su WT, et al. Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data. J Transl Med. 2019;17(1):311.PubMedPubMedCentralCrossRef Xu N, Wu YP, Ke ZB, Liang YC, Cai H, Su WT, et al. Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data. J Transl Med. 2019;17(1):311.PubMedPubMedCentralCrossRef
49.
go back to reference Russo A, Biselli-Chicote PM, Kawasaki-Oyama RS, Castanhole-Nunes MMU, Maniglia JV, de Santi ND, et al. Differential expression of prostaglandin I2 synthase associated with Arachidonic acid pathway in the Oral squamous cell carcinoma. J Oncol Pract. 2018;2018:6301980. Russo A, Biselli-Chicote PM, Kawasaki-Oyama RS, Castanhole-Nunes MMU, Maniglia JV, de Santi ND, et al. Differential expression of prostaglandin I2 synthase associated with Arachidonic acid pathway in the Oral squamous cell carcinoma. J Oncol Pract. 2018;2018:6301980.
50.
go back to reference Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick DJ, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A. 1994;91(14):6379–83.PubMedPubMedCentralCrossRef Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick DJ, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A. 1994;91(14):6379–83.PubMedPubMedCentralCrossRef
51.
go back to reference Mansour M, Schwartz D, Judd R, Akingbemi B, Braden T, Morrison E, et al. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol. 2011;38(2):537–46.PubMedCrossRef Mansour M, Schwartz D, Judd R, Akingbemi B, Braden T, Morrison E, et al. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol. 2011;38(2):537–46.PubMedCrossRef
52.
go back to reference Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab. 2008;93(10):4088–97.PubMedCrossRef Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab. 2008;93(10):4088–97.PubMedCrossRef
53.
go back to reference Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, et al. Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol. 2008;141(5):659–71.PubMedPubMedCentralCrossRef Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, et al. Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol. 2008;141(5):659–71.PubMedPubMedCentralCrossRef
54.
go back to reference Visca P, Sebastiani V, Pizer ES, Botti C, De Carli P, Filippi S, et al. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res. 2003;23(1A):335–9.PubMed Visca P, Sebastiani V, Pizer ES, Botti C, De Carli P, Filippi S, et al. Immunohistochemical expression and prognostic significance of FAS and GLUT1 in bladder carcinoma. Anticancer Res. 2003;23(1A):335–9.PubMed
55.
go back to reference Jiang B, Li EH, Lu YY, Jiang Q, Cui D, Jing YF, et al. Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer. Urology. 2012;80(2):484.e489–15.CrossRef Jiang B, Li EH, Lu YY, Jiang Q, Cui D, Jing YF, et al. Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer. Urology. 2012;80(2):484.e489–15.CrossRef
56.
go back to reference Zheng SS, Gao JG, Liu ZJ, Zhang XH, Wu S, Weng BW, et al. Downregulation of fatty acid synthase complex suppresses cell migration by targeting phosphor-AKT in bladder cancer. Mol Med Rep. 2016;13(2):1845–50.PubMedCrossRef Zheng SS, Gao JG, Liu ZJ, Zhang XH, Wu S, Weng BW, et al. Downregulation of fatty acid synthase complex suppresses cell migration by targeting phosphor-AKT in bladder cancer. Mol Med Rep. 2016;13(2):1845–50.PubMedCrossRef
58.
go back to reference Feng C, Ding G, Ding Q, Wen H. Overexpression of low density lipoprotein receptor-related protein 1 (LRP1) is associated with worsened prognosis and decreased cancer immunity in clear-cell renal cell carcinoma. Biochem Biophys Res Commun. 2018;503(3):1537–43.PubMedCrossRef Feng C, Ding G, Ding Q, Wen H. Overexpression of low density lipoprotein receptor-related protein 1 (LRP1) is associated with worsened prognosis and decreased cancer immunity in clear-cell renal cell carcinoma. Biochem Biophys Res Commun. 2018;503(3):1537–43.PubMedCrossRef
59.
go back to reference Nakamura K, Urabe Y, Kagemoto K, Yuge R, Hayashi R, Ono A, et al. Genomic characterization of non-invasive differentiated-type gastric Cancer in the Japanese population. Cancers (Basel). 2020;12(2):510.CrossRef Nakamura K, Urabe Y, Kagemoto K, Yuge R, Hayashi R, Ono A, et al. Genomic characterization of non-invasive differentiated-type gastric Cancer in the Japanese population. Cancers (Basel). 2020;12(2):510.CrossRef
60.
go back to reference Salama Y, Lin SY, Dhahri D, Hattori K, Heissig B. The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis. FASEB J. 2019;33(3):3465–80.PubMedCrossRef Salama Y, Lin SY, Dhahri D, Hattori K, Heissig B. The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis. FASEB J. 2019;33(3):3465–80.PubMedCrossRef
61.
go back to reference Meng H, Chen G, Zhang X, Wang Z, Thomas DG, Giordano TJ, et al. Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin Cancer Res. 2011;17(8):2426–33.PubMedPubMedCentralCrossRef Meng H, Chen G, Zhang X, Wang Z, Thomas DG, Giordano TJ, et al. Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin Cancer Res. 2011;17(8):2426–33.PubMedPubMedCentralCrossRef
62.
go back to reference Cao Y, Jiao N, Sun T, Ma Y, Zhang X, Chen H, et al. CXCL11 correlates with antitumor immunity and an improved prognosis in Colon Cancer. Front Cell Dev Biol. 2021;9:646252.PubMedPubMedCentralCrossRef Cao Y, Jiao N, Sun T, Ma Y, Zhang X, Chen H, et al. CXCL11 correlates with antitumor immunity and an improved prognosis in Colon Cancer. Front Cell Dev Biol. 2021;9:646252.PubMedPubMedCentralCrossRef
Metadata
Title
Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer
Authors
Xiaotao Li
Shi Fu
Yinglong Huang
Ting Luan
Haifeng Wang
Jiansong Wang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-09006-w

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine